中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 10
Oct.  2011
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2011  >  27(10): 1112-1115

CD163 and sCD163:New evaluating indicators of liver failure

Research funding:

 

  • Published Date: 2011-10-20
    Abstract
  • Liver failure is a clinical syndrome characterized by considerable hepatic cells necrosis and severe liver dysfunction.The hosts' immune reaction is abnormal in which overactivation of macrophages and secretion of cytokines play an important role in the pathogenesis of liver failure.Haemoglobin scavenger receptor (CD163) which is expressed only on monocytes and macrophages could be a marker of activated macrophages.Recent reports reveal that it may play an important role in anti-inflammation and anti-oxidation, both CD163 and sCD163 could reflect the severity of pathogenetic condition and the prognosis of patients with liver failure.So CD163 and sCD163 may be new evaluating indicators of liver failure.

     

    • FullText(HTML)
    • References(56)
  • [1]王宇明, 汤影子.重型乙型肝炎发病机制研究进展[J].传染病信息, 2008, 21 (2) :68-70.
    [1]王宇明, 汤影子.重型乙型肝炎发病机制研究进展[J].传染病信息, 2008, 21 (2) :68-70.
    [2]Moller HJ, Aerts H, Gronbaek H, et al.Soluble CD163:a mark-er molecule for monocyte/macrophage activity in disease[J].Seand J Clin Lab Invest Suppl, 2002, 62 (7) :29-33.
    [2]Moller HJ, Aerts H, Gronbaek H, et al.Soluble CD163:a mark-er molecule for monocyte/macrophage activity in disease[J].Seand J Clin Lab Invest Suppl, 2002, 62 (7) :29-33.
    [3]Madsen M, Moller HJ, Nielsen MJ, et al.Molecular charac-terization of the haptoglobin.hemoglobin receptor CD163.Ligand binding properties of the scavenger receptor cysteine-rich domain region[J].J Biol Chem, 2004, 279 (49) :51561-51567.
    [3]Madsen M, Moller HJ, Nielsen MJ, et al.Molecular charac-terization of the haptoglobin.hemoglobin receptor CD163.Ligand binding properties of the scavenger receptor cysteine-rich domain region[J].J Biol Chem, 2004, 279 (49) :51561-51567.
    [4]Van Gorp H, Delputte PL, Nauwynck HJ.Scavenger recep-tor CD163, a Jack-of-all-trades and potential target forcell-directed therapy[J].J Mol Immunol, 2010, 47 (7-8) :1650-1660.
    [4]Van Gorp H, Delputte PL, Nauwynck HJ.Scavenger recep-tor CD163, a Jack-of-all-trades and potential target forcell-directed therapy[J].J Mol Immunol, 2010, 47 (7-8) :1650-1660.
    [5]Ritter M, Buechler C, Langmann T, et al.Genomic organiza-tion and chromosomal localization of the human CD163 (M I30) gene:a member of the scavenger receptor cystein-richsuper-family[J].Biochem Biophys Res Commun, 1999, 260 (2) :466-474.
    [5]Ritter M, Buechler C, Langmann T, et al.Genomic organiza-tion and chromosomal localization of the human CD163 (M I30) gene:a member of the scavenger receptor cystein-richsuper-family[J].Biochem Biophys Res Commun, 1999, 260 (2) :466-474.
    [6]Nielsen MJ, Madsen M, Moller HJ, et al.The macrophagescavenger receptor CD163:endocytic properties of cytoplasmictail variants[J].J Leukoc Biol, 2006, 79 (4) :837-845.
    [6]Nielsen MJ, Madsen M, Moller HJ, et al.The macrophagescavenger receptor CD163:endocytic properties of cytoplasmictail variants[J].J Leukoc Biol, 2006, 79 (4) :837-845.
    [7]Nguyen TT, Schwartz EJ, West RB, et al.Expression ofCD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restrictedto the monocyte/macrophage lineage[J].Am J SurgPathol, 2005, 29 (5) :617-624.
    [7]Nguyen TT, Schwartz EJ, West RB, et al.Expression ofCD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restrictedto the monocyte/macrophage lineage[J].Am J SurgPathol, 2005, 29 (5) :617-624.
    [8]Sanchez C, Domenech N, Vazquez J, et al.The Poreine2A10 antigen is homologous to human CD163 and related tomacrophage differentiation[J].J Immunol, 1999, 162 (9) :5230-5237.
    [8]Sanchez C, Domenech N, Vazquez J, et al.The Poreine2A10 antigen is homologous to human CD163 and related tomacrophage differentiation[J].J Immunol, 1999, 162 (9) :5230-5237.
    [9]Moller HJ, Nielsen MJ, Maniecki MB, et al.Soluble Macro-phage-derived CD163:a homogenous ectodomain proteinwith a dissociable haptoglobin-hemoglobin binding[J].Im-munobiology, 2010, 215 (5) :406-412.
    [9]Moller HJ, Nielsen MJ, Maniecki MB, et al.Soluble Macro-phage-derived CD163:a homogenous ectodomain proteinwith a dissociable haptoglobin-hemoglobin binding[J].Im-munobiology, 2010, 215 (5) :406-412.
    [10]Weaver LK, Hintz-Goldstein KA, Pioli PA, et al.Pivotal ad-vance:activation of cell surface Toll-Iike receptor causesshedding of the hemoglobin scavenger receptor CD163[J].J Leukoc Biol, 2006, 80 (1) :26-35.
    [10]Weaver LK, Hintz-Goldstein KA, Pioli PA, et al.Pivotal ad-vance:activation of cell surface Toll-Iike receptor causesshedding of the hemoglobin scavenger receptor CD163[J].J Leukoc Biol, 2006, 80 (1) :26-35.
    [11]Buechler C, Ritter M, Orso E, et al.Regulation of scavengerreceptor CDl63 expression in human monocytes and macro-phages by pro-and anti-inflammatory stimuli[J].J Leu-koc Biol, 2000, 67 (1) :97-103.
    [11]Buechler C, Ritter M, Orso E, et al.Regulation of scavengerreceptor CDl63 expression in human monocytes and macro-phages by pro-and anti-inflammatory stimuli[J].J Leu-koc Biol, 2000, 67 (1) :97-103.
    [12]Zwadlo-Klarwasser G, Bent S, Haubeck HD, et al.Glu-cocorticoid-induced appearance of the macrophage subtypeRM3/1 in peripheral blood of man[J].Int Arch Allergy ApplImmunol, 1990, 91 (2) :175-180.
    [12]Zwadlo-Klarwasser G, Bent S, Haubeck HD, et al.Glu-cocorticoid-induced appearance of the macrophage subtypeRM3/1 in peripheral blood of man[J].Int Arch Allergy ApplImmunol, 1990, 91 (2) :175-180.
    [13]Kristiansen M, Graversen JH, Jacobsen C, et al.Identifica-tion of the haemoglobin scavenger receptor[J].Nature, 2001, 409 (6817) :198-201.
    [13]Kristiansen M, Graversen JH, Jacobsen C, et al.Identifica-tion of the haemoglobin scavenger receptor[J].Nature, 2001, 409 (6817) :198-201.
    [14]谷甸娜, 陈永平, 芦明芹, 等.CD163和血红素加氧酶1在急性肝衰竭大鼠模型中的表达[J].中华肝脏病杂志, 2008, 16 (12) :944-945.
    [14]谷甸娜, 陈永平, 芦明芹, 等.CD163和血红素加氧酶1在急性肝衰竭大鼠模型中的表达[J].中华肝脏病杂志, 2008, 16 (12) :944-945.
    [15]Yamazaki H, Ohta K, Tsukiji H, et al.Corticosteroid en-hances hemeoxygenase-1 production by circulation mono-cytes by up-regulating hemoglobin scavenger receptor andamplifying the receptor-mediated uptake of hemoglobin-haptoglobin complex[J].Biochem Biophys Res Commun, 2007, 358 (2) :506-512.
    [15]Yamazaki H, Ohta K, Tsukiji H, et al.Corticosteroid en-hances hemeoxygenase-1 production by circulation mono-cytes by up-regulating hemoglobin scavenger receptor andamplifying the receptor-mediated uptake of hemoglobin-haptoglobin complex[J].Biochem Biophys Res Commun, 2007, 358 (2) :506-512.
    [16]Abraham NG, Drummond G.CD163-Mediated hemoglobin-heme uptake activates macrophage HO-1, providing ananti-inflammatory function[J].Circ Res, 2006, 99 (9) :911-914.
    [16]Abraham NG, Drummond G.CD163-Mediated hemoglobin-heme uptake activates macrophage HO-1, providing ananti-inflammatory function[J].Circ Res, 2006, 99 (9) :911-914.
    [17]Otterbein LE, Bach FH, Alam J, et al.Carbon monoxide hasanti-inflammatory effects involving mitogen-activated proteinkinase pathway[J].J Nat Med, 2002, 6 (4) :422-428.
    [17]Otterbein LE, Bach FH, Alam J, et al.Carbon monoxide hasanti-inflammatory effects involving mitogen-activated proteinkinase pathway[J].J Nat Med, 2002, 6 (4) :422-428.
    [18] 谷甸娜, 陈永平, 张晓华, 等.乌司他丁对急性肝功能衰竭大鼠肝组织中血红素加氧酶-1 mRNA及蛋白表达的影响[J].中华传染病杂志, 2009, 27 (4) :207-211.
    [18] 谷甸娜, 陈永平, 张晓华, 等.乌司他丁对急性肝功能衰竭大鼠肝组织中血红素加氧酶-1 mRNA及蛋白表达的影响[J].中华传染病杂志, 2009, 27 (4) :207-211.
    [19]Philippidis P, Mason JC, Evans BJ, et al.Hemoglobin scav-enger receptor CDl63 mediates interleukin-10 release andheme oxygenase-1 synthesis:Anti-inflammatory mono-cyte-macrophage response in vitro, in resolving skin blis-ters in vivo, and after cardiopulmonary bypass surgery[J].JCirc Res, 2004, 94 (1) :119-126.
    [19]Philippidis P, Mason JC, Evans BJ, et al.Hemoglobin scav-enger receptor CDl63 mediates interleukin-10 release andheme oxygenase-1 synthesis:Anti-inflammatory mono-cyte-macrophage response in vitro, in resolving skin blis-ters in vivo, and after cardiopulmonary bypass surgery[J].JCirc Res, 2004, 94 (1) :119-126.
    [20]Van den Heuvel MM, Tensen CP, Van As JH, et al.Regula-tion of CD163 on human macrophages:cross-linking ofCD163 induces signaling and activation[J].J Leukoc Biol, 1999, 66 (5) :858-866.
    [20]Van den Heuvel MM, Tensen CP, Van As JH, et al.Regula-tion of CD163 on human macrophages:cross-linking ofCD163 induces signaling and activation[J].J Leukoc Biol, 1999, 66 (5) :858-866.
    [21]Fabriek BO, van Bruggen R, Deng DM, et al.The macrophageseavenger receptor CD163 functions as an innate immune sen-sor for bacteria[J].Blood, 2009, 113 (4) :887-892.
    [21]Fabriek BO, van Bruggen R, Deng DM, et al.The macrophageseavenger receptor CD163 functions as an innate immune sen-sor for bacteria[J].Blood, 2009, 113 (4) :887-892.
    [22]Moreno JA, Munoz-Garcia B, Martin-Ventura JL, et al.The CD163-expressing macrophages recognize and inter-nalize TWEAK:potential consequences in atherosclerosis[J].Atherosclerosis, 2009, 207 (1) :103-110.
    [22]Moreno JA, Munoz-Garcia B, Martin-Ventura JL, et al.The CD163-expressing macrophages recognize and inter-nalize TWEAK:potential consequences in atherosclerosis[J].Atherosclerosis, 2009, 207 (1) :103-110.
    [23]Hiraoka A, Horiike N, Akbar SM, et al.Expression of CD163in the liver of patients with viral hepatitis[J].Pathol ResPract, 2005, 201 (5) :379-384.
    [23]Hiraoka A, Horiike N, Akbar SM, et al.Expression of CD163in the liver of patients with viral hepatitis[J].Pathol ResPract, 2005, 201 (5) :379-384.
    [24]吴会玲.慢加急性肝衰竭内毒素血症对清道夫受体CD163作用的研究[D].武汉:华中科技大学, 2010.
    [24]吴会玲.慢加急性肝衰竭内毒素血症对清道夫受体CD163作用的研究[D].武汉:华中科技大学, 2010.
    [25]Hogger P, Sorg C.Soluble CD163 inhibits phorbol ester-in-duced lymphocyte proliferation[J].Biochem Biophys ResCommun, 2001, 288 (4) :841-843.
    [25]Hogger P, Sorg C.Soluble CD163 inhibits phorbol ester-in-duced lymphocyte proliferation[J].Biochem Biophys ResCommun, 2001, 288 (4) :841-843.
    [26]Moller HJ, Frikke-Schmidt R, Moestrup SK, et al.Serumsoluble CD163 predicts risk of type 2 diabetes in the generalpopulation[J].Clin chem, 2011, 57 (2) :291-297.
    [26]Moller HJ, Frikke-Schmidt R, Moestrup SK, et al.Serumsoluble CD163 predicts risk of type 2 diabetes in the generalpopulation[J].Clin chem, 2011, 57 (2) :291-297.
    [27]Hiraoka A, Horiike N, Akbar SM, et al.Soluble CD163 in pa-tients with liver diseases:very high levels of soluble CD163in patients with fulminant hepatic failure[J].J Gastroen-terol, 2005, 40 (1) :52-56.
    [27]Hiraoka A, Horiike N, Akbar SM, et al.Soluble CD163 in pa-tients with liver diseases:very high levels of soluble CD163in patients with fulminant hepatic failure[J].J Gastroen-terol, 2005, 40 (1) :52-56.
    [28]Moller HJ, Gronbaek H, Schiodt FV, et al.Soluble CD163from activated macrophages predicts mortality in acute liverfailure[J].J Hepatol, 2007, 47 (5) :671-676.
    [28]Moller HJ, Gronbaek H, Schiodt FV, et al.Soluble CD163from activated macrophages predicts mortality in acute liverfailure[J].J Hepatol, 2007, 47 (5) :671-676.
    • Relative Articles

  • Relative Articles

    [1]Chenlu HAN, Haijun LIANG, Daokun YANG, Haiyan CHANG, Shuai WEI, Xingwei WANG, Haili GAO. Expression levels of serum high-mobility group box 1， soluble CD163， and prostaglandin E2 in patients with hepatitis B virus-related chronic-on-acute liver failure and their value in predicting prognosis[J]. Journal of Clinical Hepatology, 2024, 40(6): 1130-1135. doi: 10.12449/JCH240610
    [2]Pengxiang YANG, Yuxue GAO, Huan LIU, Yuntai SHEN, Yunjin ZANG, Dexi CHEN. Value of Fractalkine and soluble CD40 ligand in bile in predicting liver injury after liver transplantation[J]. Journal of Clinical Hepatology, 2021, 37(4): 841-845. doi: 10.3969/j.issn.1001-5256.2021.04.023
    [3]Chen Hao, Ma JunYong, Qian LiQiang, Yin GuoWen. Value of spleen stiffness and spleen volume in predicting posthepatectomy liver failure in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(12): 2725-2729. doi: 10.3969/j.issn.1001-5256.2019.12.017
    [4]Li Yu, Tian Ying, Yang XiaoMei, Cao NingJia, Li Zhu, Zhang Hong, Zhang XianJiao. Effect of thymosin α1 on the function of CD4+CD25+CD127dim/- regulatory T cells in chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2018, 34(5): 1011-1014. doi: 10.3969/j.issn.1001-5256.2018.05.017
    [5]Wu YiChen, Yao HongYu, Wang KaiLi, Jiang QiYu, Liu Chang, Xing HanQian, Liu SuXia, You ShaoLi, Zhao Jun. Effect of plasma exchange on bioactivity of peripheral blood CD34+ cells in patients with acute-on-chronic (subacute) liver failure[J]. Journal of Clinical Hepatology, 2018, 34(11): 2383-2387. doi: 10.3969/j.issn.1001-5256.2018.11.023
    [6]Wu ShanShan, Liu HongYu, Chen QiuLian, Du ZhenShuang, Liu ChaoHui. Association between CD4+/CD8+ ratio in peripheral blood before hepatectomy for liver cancer and patient prognosis[J]. Journal of Clinical Hepatology, 2015, 31(12): 2066-2069. doi: 10.3969/j.issn.1001-5256.2015.12.019
    [7]Xian YongChao, Cheng ShuQuan, Ni Hui, Huang ChengJun. Analysis of hepatic CD4~+,CD8~+,CD20~+,and CD57~+ T lymphocytes in chronic hepatitis B patients with different HBe Ag status[J]. Journal of Clinical Hepatology, 2015, 31(4): 546-550. doi: 10.3969/j.issn.1001-5256.2015.04.017
    [8]Wang Xian, Wang ShaoYang, Huang DeDong, Chen Jian, Chen DeLiang. Analysis of short-term prognostic factors in patients with HBV-related acute-on-chronic liver failure treated with artificial liver support system[J]. Journal of Clinical Hepatology, 2014, 30(4): 367-369. doi: 10.3969/j.issn.1001-5256.2014.04.020
    [9]Wang GuangYi, Shi XiaoJu, Jiang Chao, Sun XiaoDong, Qiu Wei, Lu: GuoYue. One case of liver transplantation for liver failure due to adult- onset Still's disease[J]. Journal of Clinical Hepatology, 2014, 30(1): 67-68. doi: 10.3969/j.issn.1001-5256.2014.01.018
    [10]Jiang ShuLian, Tan ShanZhong, Wen Jian. Role of CD4+CD25+ T regulatory cells in HBeAg seroconversion during interferon antiviral[J]. Journal of Clinical Hepatology, 2012, 28(7): 528-530.
    [11]Wu YinYa, Tan ShanZhong, Zhao Lei, Sun WeiWei, Shen JianJun, Liang ZhongFeng. The changes and value of the proportion of CD4+CD25+ regulatory T cells in HBeAg (+) and HBeAg (-) ASC in peripheral blood[J]. Journal of Clinical Hepatology, 2012, 28(3): 209-211.
    [12]Zhang WenHua, Jia WenLing, Zhou ZiYing, Tang HaiTao, Wang FengMei. Investigation on the method and safety of the non-heparinized plasma exchange therapy in treating patients with hepatic failure[J]. Journal of Clinical Hepatology, 2012, 28(1): 50-52.
    [13]Zhou XinMin, Dong XuYang. Therapeutic strategies of liver failure for clinical cases[J]. Journal of Clinical Hepatology, 2012, 28(2): 93-98.
    [14]Zhang AiMin, Xin ShaoJie. Virus infection and liver failure[J]. Journal of Clinical Hepatology, 2012, 28(10): 729-731.
    [15]Shi QingFeng, Song JiKui, Zhang YingXin, Yuan JianGuo, Wang SiKui, Li QingFang, Zhao HongKui. Study on the expression of HLA-DR/CD69 on CD4+/CD8+T cells in the treatment of HBeAg-positive chronic hepatitis B with interferon alfa-2b[J]. Journal of Clinical Hepatology, 2011, 27(12): 1285-1287+1300.
    [16]Li ShuangXing, Shi LiJun, Wang XiuJie. Effects of bone marrow mesenchymal stem cells transplantation into rats with acute liver failure[J]. Journal of Clinical Hepatology, 2010, 26(6): 624-626.
    [17]Liang Jing, Kan ZhiChao, Zhang JianDong. The clinical characteristics and treatment of liver failure patients with spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2010, 26(6): 621-623.
    [18]Zhan AiQin, Liu PeiZhi, Yang Yong. Expression of CD4+CD25+Tr in the peripheral blood of hepatitis B virus in fection and its clinical significance[J]. Journal of Clinical Hepatology, 2008, 24(4): 256-258.
    [20]Zhu ZhengYan, Du Zhi, Wang YiJun, Zhang Wen, Sun BaoCun. The study on relationship between CD15, CD44v6, CD54 and invasion or metastasis of human hepatocellular carcioma[J]. Journal of Clinical Hepatology, 2001, 17(4): 244-245.
    • Supplements(0)
    • Cited By
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 4.4 %FULLTEXT: 4.4 %META: 93.3 %META: 93.3 %PDF: 2.4 %PDF: 2.4 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 2.0 %其他: 2.0 %其他: 0.5 %其他: 0.5 %Baden: 0.2 %Baden: 0.2 %Central District: 0.7 %Central District: 0.7 %China: 0.9 %China: 0.9 %Kao-sung: 0.2 %Kao-sung: 0.2 %Roscoe: 0.4 %Roscoe: 0.4 %Taoyuan District: 0.4 %Taoyuan District: 0.4 %United States: 0.2 %United States: 0.2 %[]: 0.2 %[]: 0.2 %上海: 5.3 %上海: 5.3 %东莞: 0.7 %东莞: 0.7 %佛罗里达州: 0.2 %佛罗里达州: 0.2 %北京: 11.8 %北京: 11.8 %南京: 1.1 %南京: 1.1 %南宁: 0.4 %南宁: 0.4 %厦门: 0.4 %厦门: 0.4 %台北: 0.4 %台北: 0.4 %台州: 0.4 %台州: 0.4 %合肥: 0.2 %合肥: 0.2 %吉林: 0.4 %吉林: 0.4 %哥伦布: 0.4 %哥伦布: 0.4 %大连: 0.2 %大连: 0.2 %天津: 0.4 %天津: 0.4 %姬路: 0.4 %姬路: 0.4 %宣城: 0.2 %宣城: 0.2 %广州: 0.7 %广州: 0.7 %张家口: 0.9 %张家口: 0.9 %成都: 0.2 %成都: 0.2 %扬州: 0.2 %扬州: 0.2 %无锡: 0.2 %无锡: 0.2 %昆明: 0.5 %昆明: 0.5 %杭州: 0.9 %杭州: 0.9 %桂林: 0.2 %桂林: 0.2 %桃园: 0.2 %桃园: 0.2 %榆林: 0.2 %榆林: 0.2 %武汉: 0.9 %武汉: 0.9 %洛阳: 0.2 %洛阳: 0.2 %济南: 0.4 %济南: 0.4 %海口: 0.2 %海口: 0.2 %深圳: 0.5 %深圳: 0.5 %温州: 0.2 %温州: 0.2 %眉山: 0.4 %眉山: 0.4 %石家庄: 0.5 %石家庄: 0.5 %芒廷维尤: 34.8 %芒廷维尤: 34.8 %芝加哥: 1.3 %芝加哥: 1.3 %苏州: 0.2 %苏州: 0.2 %葵涌: 0.2 %葵涌: 0.2 %衡水: 0.2 %衡水: 0.2 %衢州: 0.4 %衢州: 0.4 %西宁: 20.2 %西宁: 20.2 %西安: 0.2 %西安: 0.2 %西雅图: 0.2 %西雅图: 0.2 %邯郸: 0.2 %邯郸: 0.2 %郑州: 2.0 %郑州: 2.0 %重庆: 0.2 %重庆: 0.2 %金昌: 0.2 %金昌: 0.2 %长春: 0.7 %长春: 0.7 %长沙: 2.9 %长沙: 2.9 %青岛: 0.2 %青岛: 0.2 %首尔: 0.2 %首尔: 0.2 %香港: 0.2 %香港: 0.2 %其他其他BadenCentral DistrictChinaKao-sungRoscoeTaoyuan DistrictUnited States[]上海东莞佛罗里达州北京南京南宁厦门台北台州合肥吉林哥伦布大连天津姬路宣城广州张家口成都扬州无锡昆明杭州桂林桃园榆林武汉洛阳济南海口深圳温州眉山石家庄芒廷维尤芝加哥苏州葵涌衡水衢州西宁西安西雅图邯郸郑州重庆金昌长春长沙青岛首尔香港

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (511) PDF downloads(352) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2509]YesterdayPV[4800]TodayIP[222]TodayPV[432]Online[3]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return